Adamax is a synthetic nootropic peptide built on the Semax backbone with two pharmacokinetic modifications: N-terminal acetylation and a C-terminal adamantane group. The rationale is sound on paper, but Adamax has never been studied independently in any species. Its RQS score reflects the actual evidence base, not the theoretical one.
| Dimension | Max | Notes | Score |
|---|---|---|---|
| Study Design | 25 | No published study of Adamax exists in any species — not in vitro, not animal, not human. Scored 2 rather than 0 to reflect the well-characterized preclinical evidence for the parent compound Semax, from which structural inferences are made. | 2 / 25 |
| Sample Size | 20 | No human participants. No animal participants in any study of Adamax itself. | 0 / 20 |
| Replication | 20 | Zero replication. There is nothing to replicate. No single published study of the compound exists under its own name in any database. | 0 / 20 |
| Journal Impact Factor | 15 | No peer-reviewed journal publication on Adamax. The 2 points reflect low-IF Russian pharmacology journals where Semax parent research appears -- a generous proxy given Adamax itself has no journal record. | 2 / 15 |
| Funding Independence | 10 | The lineage is Russian academic (Institute of Molecular Genetics). However, the compound now circulates almost exclusively through gray-market research chemical vendors. No formal research funding exists to assess. Partial credit for the academic origin of the parent compound program. | 4 / 10 |
| Population Diversity | 5 | No human data. Not applicable. | 0 / 5 |
| Researcher h-Index | 5 | Credited to the Semax research lineage (Institute of Molecular Genetics, Russian Academy of Sciences). The researchers behind the parent program have credible academic profiles. Adamax itself has no identifiable primary researcher. | 3 / 5 |
| Total | 100 | 11 / 100 |
Anecdotal reports in nootropic communities describe Adamax as producing stronger and longer-lasting cognitive effects than Semax, with users noting enhanced focus, improved verbal fluency, and extended duration per dose. These reports are entirely unverifiable and cannot be distinguished from placebo response. PeptideClear does not validate or weight anecdotal claims; they are surfaced here as community signal only.